Finance

Lists
Why is PLRX down 3.88%?
Dive Deeper
PLRX:NASDAQ
Pliant Therapeutics Inc
$0.99
-3.88%
(-0.040) 1D
$0.99
0.00% (0.00)
After hours
Closed: Oct 7, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PLRX...
Open
$1.03
High
$1.03
Low
$0.97
Mkt. cap
61.30M
Avg. vol.
361.72K
Volume
756.50K
52-wk high
$1.95
52-wk low
$0.97
EPS
-$1.50
Beta
1.27
Shares outstanding
61.92M
No. of employees
49
Open
$1.03
High
$1.03
Low
$0.97
Mkt. cap
61.30M
Avg. vol.
361.72K
Volume
756.50K
52-wk high
$1.95
52-wk low
$0.97
EPS
-$1.50
Beta
1.27
Shares outstanding
61.92M
No. of employees
49
News stories
From web sources and news partners
About Pliant Therapeutics Inc
CEO-
Employees49
Founded2015
HeadquartersSouth San Francisco, California, United States
SectorPharmaceutical industry
Websitepliantrx.com
Analyst ratings
Based on 5 analysts giving stock ratings to PLRX in the past 3 months
Hold
Buy
0
Hold
4
Sell
1
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for PLRX in the last 3 months.
Highest
Current $0.99
$3.00 (+203.03%)
Average
$2.50 (+152.53%)
Lowest
$2.00 (+102.02%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brian Cheng
J.P. Morgan
Sell
Maintained
-
-
08/17/2026
Edward Nash
Canaccord Genuity
Hold
Reiterated
$3.00
+203%
08/13/2026
Unknown Analyst
Oppenheimer
Hold
Maintained
-
-
08/12/2026
Brian Abrahams
RBC Capital
Hold
Maintained
$2.00
+102%
08/11/2026
Joseph Stringer
Needham
Hold
Maintained
-
-
08/12/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$3.00
+203%
05/12/2026
Last report
Aug 11, 2026
Fiscal period
Q2 2026
-$0.36 / -$0.34
-4.43%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
17.84M
13.38M
13.58M
16.73M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.33M
7.69M
8.19M
7.14M
Operating expense
28.17M
21.08M
21.77M
23.86M
Total operating expenses
28.17M
21.08M
21.77M
23.86M
Operating income
-28.17M
-21.08M
-21.77M
-23.86M
Other non operating income
-
-
-
-
EBT including unusual items
-26.30M
-23.58M
-20.04M
-22.37M
EBT excluding unusual items
-26.20M
-19.25M
-20.04M
-22.37M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-26.30M
-23.58M
-20.04M
-22.37M
Net profit margin
-
-
-
-
Earnings per share
-0.43
-0.35
-0.32
-0.36
Interest and investment income
2.78M
1.96M
1.73M
1.49M
Interest expense
-815.00K
-136.00K
-
-
Net interest expenses
1.97M
1.83M
1.73M
1.49M
Depreciation and amortization charges
-
-
-
-
EBITDA
-27.73M
-20.71M
-21.51M
-23.61M
Gain or loss from assets sale
-44.00K
-
-94.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps